# Ipamorelin: Clean Pharmacology, Thin Clinical File

> Ipamorelin: One Trial, One PK Study - Growth Hormone Axis Research Peptides — Ipamorelin among the Growth Hormone Axis research peptides: the selective GHS-R1a agonist, its single Phase 2 trial in 114 adults, its human pharmacokinetics, the rodent record, and the class-level cardiac signal that frames it.

**MEMBER 01 / GHRP ARM**

The first selective growth hormone secretagogue - measured precisely in cells, rats and swine, and tested once in people against an endpoint it did not meet.

## The short version

Ipamorelin is a five-amino-acid synthetic peptide that binds the ghrelin receptor on pituitary cells and triggers a single burst of growth hormone. Its distinguishing feature in the laboratory literature is selectivity: unlike the older peptides in its family, it raises growth hormone without dragging stress hormones such as cortisol up alongside it.

The applied record is thinner than the mechanism suggests. Ipamorelin has never been approved as a drug anywhere. It has one published Phase 2 trial, in patients recovering from bowel surgery, and that trial did not meet its primary endpoint [3]. It has one human pharmacokinetic study, in eight volunteers per dose level [4]. Nearly everything else known about it comes from rats, swine and cell preparations.

What follows reports those studies the way they were designed and published: species, sample size, route, duration and result, in that order, with the gaps named rather than filled in.

## What ipamorelin is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 - alpha-aminoisobutyric acid at position one, with D-2-naphthylalanine and D-phenylalanine conferring resistance to protease breakdown. It was derived from the earlier peptide GHRP-1 by removing the central Ala-Trp dipeptide, and it appears in the literature under the development code NNC 26-0161 and as ipamorelin acetate.

Structurally it belongs to the growth-hormone-releasing peptides, or GHRPs, a family that acts through the ghrelin receptor rather than through the growth-hormone-releasing-hormone receptor used by GHRH analogues such as sermorelin and tesamorelin (Egrifta). That distinction matters more than the shared word *secretagogue* implies, and it is precisely why ipamorelin and a GHRH analogue are so often discussed as a pair.

Its regulatory position is unambiguous. There is no approval in any jurisdiction and it is marketed only as a research chemical. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following nominator withdrawal, and reviewed both the acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is prohibited in sport at all times under WADA category S2, with established urine-detection methods.

## The mechanism, stated precisely

Ipamorelin is a selective agonist at the ghrelin / growth hormone secretagogue receptor, GHS-R1a, expressed on pituitary somatotrophs. Binding raises intracellular calcium through a Gq-coupled pathway and produces a discrete pulse of growth hormone release. It does this by a mechanism distinct from - and complementary to - GHRH, which is the entire basis for combining it with a GHRH analogue.

The defining pharmacological feature is what it does *not* do. In its founding characterization, ipamorelin released growth hormone potently in primary rat pituitary cells, in anesthetized rats and in conscious swine, with a swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6, yet did not raise ACTH or cortisol above the level seen with GHRH itself even at doses more than 200-fold higher than its growth-hormone ED50 [6]. That result is what made it the first highly GH-selective growth hormone secretagogue, and it remains the single most-cited fact about the compound.

GHS-R1a is not confined to the pituitary. The receptor is also expressed on enteric and vagal neurons governing gastric motility, on pancreatic islet cells, and in the hypothalamic circuitry that regulates appetite. That distribution is why a compound designed to act on the pituitary has a gastrointestinal trial history and a class-level effect on hunger.

## What the studies measured

**The human trial.** The only published Phase 2 randomized controlled trial of ipamorelin (NCT00672074) enrolled 114 adults undergoing bowel resection and gave 0.03 mg/kg intravenously twice daily for up to seven days, with time to first tolerated meal as the primary endpoint. It missed: a median of 25.3 hours on ipamorelin against 32.6 hours on placebo, p=0.15. Treatment-emergent adverse events were reported in 87.5% of the ipamorelin arm and 94.8% of the placebo arm [3]. The point estimate favored the drug; the trial did not establish the effect.

**The human pharmacokinetics.** Population pharmacokinetic and pharmacodynamic modeling in healthy male volunteers - eight per dose level, five fifteen-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg - found dose-proportional kinetics with a terminal half-life of approximately two hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The growth-hormone response peaked at about 0.67 hours, roughly 40 minutes after dosing, as a single discrete pulse [4]. This is the dataset that anchors every statement about how long ipamorelin acts, and it describes intravenous infusion in healthy men - not the subcutaneous route that dominates off-label use, for which no published human pharmacokinetic characterization exists.

**The animal work.** Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided across three daily administrations for fifteen days, raised the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometers per day on vehicle to 44, 50 and 52 micrometers per day respectively, with no change in total IGF-1, IGF binding proteins or bone turnover markers [5]. The absence of an IGF-1 shift in a study that clearly moved a growth endpoint is the kind of detail an applied reading should not skip past.

The most recent published in-vivo study, in ferrets in 2024, found that intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the final day of the delayed phase, 48 to 72 hours, while producing no anti-emetic effect in either the acute or the delayed phase - in contrast to intracerebroventricular anamorelin, which reduced acute emesis by 60% in the same work [1].

**The combination review.** A 2026 narrative review from the USC Keck School of Medicine reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, while concluding that the evidence is limited to animal studies, that safety and dosing data remain unknown for ipamorelin, and that significant further research is required before any clinical recommendation can be made [7].

## Reported effects, cautions and safety

The first part of this section is anecdotal, not clinical evidence. It summarizes what people using ipamorelin outside any study describe in research-use communities, where dose, purity, source and concurrent training and diet are all unverified, and none of which has been measured in a trial. No doses are reported here because none of these accounts carry a verified one.

Deeper and more restorative sleep is by a wide margin the most frequently reported benefit - falling asleep faster, sleeping more deeply, waking more rested - often accompanied in the first week or two by unusually vivid dreams that are described as settling afterward. Faster physical recovery and reduced post-training soreness are also frequently reported. A gradual shift toward leaner body composition over roughly five to twelve weeks is reported less often and is heavily confounded by concurrent diet and training.

On the adverse side, a transient facial flush or head-rush shortly after injection is frequently reported and commonly compared to a niacin flush. Occasional reports include tingling or numbness in the hands and feet, mild water retention and puffiness in the early weeks, increased hunger in the hours after dosing, injection-site redness or itching, brief light-headedness or a spacey feeling, and a sense that effects diminish after three to four months of uninterrupted use. All of it is uncontrolled self-report.

**Cautions grounded in mechanism and literature.** Growth hormone drives hepatic IGF-1 production and IGF-1 is a well-characterized mitogen, so chronically raising growth-hormone pulse amplitude raises a theoretical concern in the presence of active or recent malignancy. No ipamorelin-specific carcinogenicity or tumor-promotion study exists in humans; the caution is mechanistic and class-level rather than derived from an observed oncologic event.

Growth hormone is also a counter-regulatory hormone that reduces peripheral insulin sensitivity, and ipamorelin has a separate, GH-independent insulinotropic action on pancreatic islet cells demonstrated in ex vivo rat tissue. That dual influence makes its net glycemic effect unpredictable in anyone with pre-existing insulin dysregulation, and no human glycemic data exist at research-use exposures.

The clearest class-level safety signal is cardiac, and it comes from a different molecule. An integrated preclinical safety-pharmacology study of the GHS-R1a agonist GSK894281 found dose-dependent myocardial degeneration and necrosis in rats after 28 days of oral dosing, detectable by histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated [2]. Ipamorelin itself was not the tested compound, and no equivalent long-duration cardiovascular study of ipamorelin exists in any species - which is the point.

Because the receptor is expressed in hypothalamic appetite circuitry, the class carries an orexigenic signal that ipamorelin's GH selectivity does not neutralize. And the plain gaps stand: no Phase 3 trial, no long-term human safety database, and research-grade material from unregulated suppliers with no assurance of peptide identity, purity or sterility.

## Where it sits on the growth-hormone axis

Ipamorelin is the ghrelin-receptor arm of this hub. Its role in the applied literature is not as a stand-alone therapy - the one serious attempt at that missed its endpoint [3] - but as the selective half of a two-receptor idea: pair a GHRP with a GHRH analogue so that two independent pathways produce a larger pulse than either alone.

That idea is the subject of the next page, and it is worth stating plainly what supports it and what does not. What supports it is receptor pharmacology, including a cell-culture experiment in which co-activating the cloned growth-hormone-secretagogue and GHRH receptors in transfected HeLa cells produced a cyclic AMP response roughly twice that of GHRH-receptor activation alone [12]. What does not support it is any controlled human outcome trial, because none has been run.

Marketing for ipamorelin has consistently run ahead of that record: promotion for anti-aging, fat loss and muscle gain rests on mechanism and short rodent studies rather than on controlled human outcome trials. The honest summary is that ipamorelin is an unusually clean piece of receptor pharmacology attached to an unusually thin clinical file, and the two should not be mistaken for one another.

---

An independent digest of the growth-hormone-axis literature that reports sample sizes, endpoints and effect sizes exactly as published - not a clinic, not a supplier, and not a source of dosing advice.